Gilead and BeiGene participated in a round for the immuno-oncology therapeutics developer in a round that came seven months after it raised $43m.

Shoreline Biosciences, a US-based oncological immunotherapy developer, raised $140m in a funding round featuring biopharmaceutical companies BeiGene and Gilead yesterday, the latter through immuno-oncology drug subsidiary Kite.

Healthcare-focused investment firm Ally Bridge Group led the round, which included Eventide Asset Management, Irving Investors, Piper Heartland Healthcare Capital, Superstring Capital, Stork Capital, Kingdon Capital and NS Investment.

Cormorant Capital, Commodore Capital, Wedbush Healthcare Partners, Janus Henderson Investors, Boxer Capital and BVF Partners filled out the participants together with an unnamed global…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn